Advances in Cellular and Molecular Treatment of Autoimmune Diseases—Second Edition

Dear Colleagues,

Lately, there has been a world-wide increase in the prevalence and incidence of autoimmune diseases. Hence, extensive research is being conducted in order to identify the causes and risk factors of autoimmune diseases. Within the pathophysiology of autoimmune diseases, this has revealed the implication of various factors in their pathogenesis. The treatment of autoimmune diseases has been the subject of academic study in recent years. Corticosteroids may be applied as early treatment. Disease-modifying non-biologic drugs, such as methotrexate, leflunomide, sulfasalazine and hydroxychloroquine, have been used and may alter disease prognosis. Biologic agents targeting cellular and molecular targets have been introduced in the treatment of autoimmune diseases. They have induced disease remission and may have altered disease progression and long-term disease prognosis. Biologic agents may be used either intravenously or subcutaneously. However, they are costly. Therefore, biosimilars of these agents have been introduced in the treatment of autoimmune diseases. The concurrent application of non-biologic disease-modifying agents and biologics is being discussed. Currently, we have diverse effective agents targeting cellular and molecular targets in the treatment of autoimmune diseases. This has enabled the modification of treatment regimens to the needs of each individual patient.

Dr. Panagiotis Athanassiou
Prof. Dr. Dimitrios P. Bogdanos
Dr. Ifigenia Kostoglou-Athanassiou
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.